Latest Healthcare News

Page 1 of 182
Chimeric Therapeutics has secured a $1.785 million advance against its anticipated FY26 Research and Development Tax Incentive to bolster its clinical trial pipeline and working capital.
Ada Torres
Ada Torres
2 Mar 2026
Avecho Biotechnology has completed recruitment for the interim analysis cohort of its pivotal Phase III trial for a CBD insomnia treatment, with results expected in June 2026. This milestone could significantly de-risk the program and unlock major market opportunities.
Ada Torres
Ada Torres
2 Mar 2026
Freedom Care Group Holdings outlines a strategic recovery plan following the suspension of its securities and liquidation of its main operating subsidiary, aiming to restore shareholder value and regain ASX listing.
Ada Torres
Ada Torres
27 Feb 2026
Osteopore Limited reported an 11% increase in revenue to $3.06 million for 2025, alongside a wider net loss of $3.72 million as it invests heavily in product development and regulatory compliance. The company also expanded its footprint with a new Singapore subsidiary.
Ada Torres
Ada Torres
27 Feb 2026
Peak Processing Limited reported a sharp 47.7% revenue drop and a 257.7% increase in losses for H1 2026, alongside a significant asset impairment and ongoing going concern concerns.
Ada Torres
Ada Torres
27 Feb 2026
Argent BioPharma reported a significantly reduced half-year loss of A$2.9 million, progressing a strategic acquisition to bolster its CannEpil drug pipeline and securing up to A$11 million in new funding.
Ada Torres
Ada Torres
27 Feb 2026
SDI Limited reported a modest 2% dip in net profit for H1 FY26 despite a 2.7% rise in sales, driven by growth in aesthetics and exports. The company faces challenges from regulatory bans on Amalgam products while advancing plans for manufacturing upgrades and a potential acquisition.
Ada Torres
Ada Torres
27 Feb 2026
Recce Pharmaceuticals reported a doubling of its net loss for the half-year ended December 2025 amid significant progress in its anti-infective drug development and a substantial funding boost. The company is advancing Phase 3 trials and expanding its patent portfolio while managing financial pressures.
Ada Torres
Ada Torres
27 Feb 2026
Nexalis Therapeutics reported a widening loss of $1.83 million for 2025, reflecting increased investment in product development and marketing. Despite the loss, the company boosted its cash reserves through equity raises and borrowings.
Ada Torres
Ada Torres
27 Feb 2026
Epsilon Healthcare Limited has reported a robust recovery in 2025, with revenue climbing 68% to $9.39 million and net losses shrinking by 63%, driven by growth in contract manufacturing and a new pharmacy division.
Ada Torres
Ada Torres
27 Feb 2026
Uscom Limited has completed the sale of all its international subsidiaries, recording a significant gain but ceasing trading activities and remaining suspended on the ASX. The company now aims to secure a new business to resume operations.
Ada Torres
Ada Torres
27 Feb 2026
Botanix Pharmaceuticals reports a surge in Sofdra sales driving revenue to $16.5 million, yet the company records a $33.2 million loss amid expanded marketing and operational costs. A $45 million capital raise aims to support growth and supply chain improvements.
Ada Torres
Ada Torres
27 Feb 2026